Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-controlled Study of Inebilizumab in Participants With Autoimmune Hepatitis

NCT07598825 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07598825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07598825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-controlled Study of Inebilizumab in Participants With Autoimmune Hepatitis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 7, 2026
Completion date
February 11, 2034
Enrollment
180 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

aih, autoimmune hepatitis